These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: IMMULITE OM-MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors.
    Author: Gebauer G, Rieger M, Jäger W, Lang N.
    Journal: Anticancer Res; 1999; 19(4A):2535-6. PubMed ID: 10470190.
    Abstract:
    Measurement of CA125 is well established in the diagnosis and follow-up of ovarian cancer. CA125 determination is usually performed with the monoclonal antibodies OC125 and M11. For the IMMULITE OM-MA chemoluminsence assay (DPC Biermann, Bad Nauheim, Germany) the monoclonal antibody OV185 is used. We analysed CA125 serum concentrations of patients with benign and malignant ovarian tumors with the IMMULITE OM-MA assay by defining a cut-off at 90% specificity level. Sera of 130 patients with benign and 119 patients with malignant ovarian tumors at different FIGO stages were analysed. By calculating a cut-off of 46 U/ml, in 87 ovarian cancer patients, elevated CA125 concentrations were detected (78% sensitivity). There were no significant differences between CA125 concentrations of tumors of different histological type. The measurement of CA125 by IMMULITE OM-MA is a simple and sensitive procedure.
    [Abstract] [Full Text] [Related] [New Search]